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Combination,” “Usually Avoid Combination,” “Take Precautions,” “No Special Pre-
cautions.” An additional option of “Not Sure” was offered to prevent guessing. The 
second outcome of interest was “DDI Recognition,” where students were given credit 
for an item if they identiﬁed a DDI. An answer of any interaction indication for a non-
interacting pair was considered incorrect for both analyses. Due to the skewed distribu-
tions of the data, nonparametric Freidman tests compared pretest and posttest scores 
for all three groups. Post hoc Wilcoxon Rank sum tests were performed for each indi-
vidual student group to determine if the posttest assessment score was signiﬁcantly 
greater than the pretest assessment score. RESULTS: DDI Knowledge assessment 
response rates from each group included 63 pharmacy students (82%), 73 medical 
students (61%), and 29 nurse practitioner students (100%). The mean management 
strategy score change for pharmacy students was 5.7 (SD = 3.7), 8.6 (SD = 3.7) for 
medical students, and 8.2 (SD = 2.8) for nurse practitioner students. The mean data 
recognition score change for pharmacy students was 3.7 (SD = 3.1), 8.52 (SD = 3.5) for 
medical students, and 9.2 (SD = 2.3) for nurse practitioner students. Posttest scores for 
each student group were signiﬁcantly greater than pretest scores (p < 0.001). CON-
CLUSIONS: The educational DDI session signiﬁcantly affected the DDI knowledge of 
health care professional students participating in the study.
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OBJECTIVES: American Diabetes Association and American Psychiatric Association 
published monitoring guidelines in February 2004 in light of the concern for metabolic 
risks associated with Second Generation Antipsychotics (SGAs). This study evaluated 
how well clinicians monitored glucose, lipids, body mass index (BMI) and blood 
pressure of those on SGAs and assessed the impact of issuance of the guidelines. 
METHODS: A retrospective analysis of an electronic medical record database for 
2001–2008 was conducted. Naïve monotherapy patients with at least one prescription 
for any of the SGAs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone) were identiﬁed. Two scenarios were evaluated during a one-year follow 
up: 1) “Any”: Monitored at least once, and 2) “Full”: Monitored for the recommended 
frequency. Impact on monitoring patterns was evaluated by quarterly time intervals 
using segmented time-series design. RESULTS: The sample consisted of 24,826 
patients with mean age of 47.9 years and 61% female. Olanzapine was most fre-
quently prescribed with >40% of the sample receiving it. In “Any” scenario blood 
pressure was monitored for 93% of patients, followed by BMI (75%), glucose (63%) 
and lipids (40%). In “Full” scenario the results were 74%, 27%, 26% and 20%, 
respectively. Pre- and post-guideline monitoring compared as: “For Any”; BP (92%, 
94%), BMI (66%, 77%), Glucose (60%, 65%), Lipids (36%, 41%) “For Full”; BP 
(72%, 75%), BMI (23%, 27%), Glucose (23%, 27%), Lipids (17%, 20%). Segmented 
regression analysis suggests increases in monitoring were statistically signiﬁcant: 
“Any”; Glucose (1.4%, p = 0.003), Lipids (1.0%, 0.008), BP (0.6%, p = 0.006) and 
“Full”; Glucose (1.0%, p = 0.002) and BP (1.3%, p = 0.004) per quarter in the 
post–guideline period. CONCLUSIONS: Monitoring was infrequent in the full moni-
toring scenario and improved only modestly from pre- to post-guideline period. 
Measures should be undertaken to increase awareness amongst patients and clinicians 
with regards to metabolic side-effects associated with SGAs.
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OBJECTIVES: Shorter length of stay (LOS) has been associated with perioperative 
bowel resection (BR) care pathway use for elective procedures, yet little is known 
about how characteristics of hospitals with such pathways may affect LOS. This study 
examined differences between hospitals with and without elective BR pathways and 
surgeons in these settings. METHODS: A cross-sectional, web-based survey was 
conducted among general and colorectal surgeons regarding their last elective BR 
patient. To qualify, surgeons had to be licensed to practice in US, in practice 2–30 
years, and conduct at least 1 BR/typical month. Logistic regression was conducted to 
determine whether care pathway presence in hospitals was associated with a shorter 
LOS, deﬁned as <4 days. Controlling variables included: surgeon specialty, years in 
practice, age, ethnicity, gender, BR surgery volume. Hospital variables included: 
practice type, location, region, number of beds, presence of electronic medical record. 
Statistical signiﬁcance was deﬁned as p < 0.10. RESULTS: Data were analyzed from 
91 general and 112 colorectal surgeons from their most recent laparoscopic BR. 
Thirty-ﬁve percent practice in a hospital with elective BR perioperative care pathways 
which contained accelerated GI recovery components. The multivariate logistic regres-
sion showed that hospitals with elective BR care pathways were more likely to have 
a shorter LOS (<4 days) (Odds Ratio: 2.40, p < 0.01). A shorter LOS (<4 days) was 
also associated with fewer years in practice (2 to 15 years, p < 0.05) and working in 
a practice that is equally hospital and ofﬁce/clinic based (p < 0.01). CONCLUSIONS: 
This analysis provides evidence that, after controlling for numerous surgeon and 
hospital characteristics, the presence of care pathways at the hospital level is associated 
with shorter LOS for laparoscopic BR patients. While self-reported, these data provide 
a good ﬁrst step at deﬁning additional research to determine the role of care pathways 
on patient outcomes after BR.
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OBJECTIVES: We examined the effect of duration of overlap for patients who bridged 
from low weight molecular heparin to warfarin for patients who underwent total hip 
and total knee replacement surgery. METHODS: A retrospective study (January 1, 
2005 to December 31, 2007) was conducted using a subset of the MarketScan Hospital 
Drug Database and its linked outpatient ﬁles from the Market Scan Commercial and 
Medicare Supplemental database. Patients’ demographic, clinical and provider charac-
teristics were compared using Chi-square testing and standardized differences. Risk-
adjusted event rates were estimated using the Poisson regression model. RESULTS: The 
linked database is comprised of 2280 enrollees, of whom 1769 met the eligibility crite-
ria: 490 underwent hip replacement surgery and 1279 underwent knee replacement 
surgery. Fifteen percent of these patients received combination therapy, including 75 
patients in the hip replacement surgery group and 189 in the knee replacement surgery 
group. Each day with overlap decreased the risk-adjusted incidence rate of venous 
thromboembolism (VTE) 0.857 times (CI: 0.7284–0.957) for patients who underwent 
major orthopedic surgery. The rates were 0.957 times (CI:0.904–0.987) lower for 
major bleeding and 0.895 times (CI:0.737–0.967) lower for minor bleeding for each 
day of overlap. CONCLUSIONS: Duration of bridging therapy varies widely and does 
not appear to be consistent with published guidelines.
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OBJECTIVES: (1) To analyze how overall and condition-speciﬁc preventable hospi-
talization (PH) rates changed over time (1995–2005), and 2) To analyze how PH rates 
varied across small market areas and whether the spatial distribution patterns changed 
over time. METHODS: The study uses hospital discharge data from the Healthcare 
Cost and Utilization Project (HCUP) State Inpatient Databases (SID) for the states—
AZ, CA,OR,WA, MA, MD, NJ, and NY for 1995 and 2005. The unit of analysis is 
the Primary Care Service Area (PCSA). Unadjusted and age-adjusted PH rates were 
computed by PCSA for overall and condition-speciﬁc trends. Coefﬁcient of variation 
(CV) was used as an indicator of small area variation. RESULTS: The 1995–2005 
trends reveal that elderly PH rates per 1000 total discharges were higher for eastern 
states than western states for the elderly, while the magnitude of variation across 
PCSAs was lower among eastern states than in western states. Adult PH rates remained 
steady over time as a whole in eight states, with rates consistently lower than the 
elderly PH rates. The combined results for all eight states show that, small area varia-
tion declined between 1995 and 2005 for both elderly (0.25 to 0.20) and adults (0.33 
to 0.30), indicating a greater decline in variation among the elderly compared to 
adults. Elderly hospitalization rates were highest for CHF, bacterial pneumonia, 
kidney/UTI and angina. Adult hospitalization rates were the highest for bacterial 
pneumonia, asthma, CHF and cellulitis. CONCLUSIONS: The study shows that in 
the last decade PH rates declined in eight states for both elderly and adults. Along 
with the declining trends, there was also a decline in variation across primary care 
markets for both adults and the elderly. The reductions were greater in the elderly 
than among the adults in both PH rates as well as small area variations in these rates.
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MEDICATION THERAPY QUALITY: A REVIEW OF MEASURES AND 
CONCEPTUAL FRAMEWORK TO ALIGN PHYSICIANS AND 
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OBJECTIVES: US efforts to improve the quality of medication therapy are expanding 
through inclusion of medication measures in the CMS Physician Quality Reporting 
Initiative (PQRI), NCQA Health Plan Employer Data and Information Set (HEDIS), 
and testing of pharmacy measures by the Pharmacy Quality Alliance (PQA). Our 
objectives were to 1) review outpatient physician and pharmacy measures for 3 major 
chronic diseases; 2) examine conceptual overlap between the measures; and 3) propose 
a framework for integrating the measures to foster a team approach to quality. 
METHODS: Physician measures for diabetes, dyslipidemia, and asthma were obtained 
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from PQRI and HEDIS 2010 requirements; pharmacy measures included 14 PQA 
measures being tested for these diseases. Measures were reviewed to identify: 1) type 
(process/outcome) 2) constructs; and 3) data requirements (pharmacy, medical, labora-
tory). RESULTS: Forty-eight measures were included (13 HEDIS, 21 PQRI, 14 PQA). 
HEDIS and PQRI measures for diabetes and dyslipidemia emphasize outcomes 
(achievement of Hgb A1c and LDL goals) and % receiving recommended screenings, 
while PQA measures emphasize process (adherence as gaps in therapy and proportion 
of days covered), excessive doses of diabetes medications, and suboptimal treatment 
(% on diabetes prescription without an ACEI or ARB). HEDIS, PQRI, and PQA 
measures for asthma assess use of controller medications, though 1 PQA measure also 
assesses overuse of beta agonists. Differences in the types and constructs of measures 
suggest opportunities for alignment. A bi-level framework that employs reporting 
pharmacy measures among patients who have not met the physician measure may 
facilitate a team approach for diabetes and hypertension quality, though this 
would only be feasible for organizations holding both medical and pharmacy data. 
CONCLUSIONS: Medication quality measures are of increasing importance, yet 
available physician and pharmacy measures differ. Findings suggest that testing a 
bi-level framework for diabetes and hypertension pharmacy quality measurement 
would be worthwhile.
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OBJECTIVES: Authorized generics (AGs) are products manufactured by a patent 
holder but marketed by a subsidiary or a third party company. AGs might increase 
competition and reduce generic prices when launched during the 180-day exclusivity 
period of an independent generic(s) (IGs). AGs launched during IG exclusivity might 
also present a long-term disadvantage to consumers by delaying timely entry of gener-
ics. The objectives of this study were: 1) to determine the trend in market share of 
AGs during the ﬁrst six months for drugs launched with a ﬁrst-ﬁler(s) 180-day exclu-
sivity; 2) to determine the trend in market share of AGs for the ﬁrst six months for 
drugs launched without ﬁrst-ﬁler(s) exclusivity. METHODS: Five drugs were selected 
as cases to assess the effect of AGs launched during the exclusivity of IGs on market 
share of the brand and generic products. Each product selected had three subcatego-
ries: a brand name drug, an AG and at least one IG on the market. The unit of analysis 
was the number of prescriptions dispensed, without regard to the dispensed quantity. 
RESULTS: At the end of the ﬁrst year, market shares of AGs launched with the 
exclusivity of an IG in the cases of Zocor®, Proscar® and Norvasc® were 37%, 52% 
and 49%, respectively. Meanwhile, market shares of AGs launched without the 
exclusivity of an IG in the cases of Arava® and Ambien® were 21% and 14%, 
respectively. CONCLUSIONS: AGs launched during IG exclusivity dominated the 
market and had the largest market share when compared to any other single market 
participant for the case. AGs launched during IG exclusivity obtain a dominant market 
share position and in the long run might discourage IG companies from timely generic 
introductions. Policy limiting the entry of AGs during the exclusivity of IG exclusivity 
might prevent delayed generic entry.
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DESCRIPTION AND EVALUATION OF THE KNOWLEDGE OF THE 
BRASILIA POPULATION FOR THE POLITICS OF ECONOMIC MEDICINE 
REGULATION IN BRAZIL
Araujo MAM, Rebelo FM, Freitas PC, Alaver RT
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OBJECTIVES: The primary objective was to evaluate the knowledge of the drugstore 
consumers from Brasilia and workers of ANVISA, for the regulation of prices of 
medicines. The speciﬁc objectives were to assess the knowledge of the populations on 
PMC, different price of generic medicines, estimate monthly expenses of the two 
samples and a preliminary comparative analysis between the two samples. METHODS: 
The study developed is a cross descriptive and analytical study. Based in the applica-
tion of different questionnaires for to assess the knowledge about regulation of prices 
of medicines and consumption habits of consumers interviewed in the door of the 
drugstore and workers of ANVISA. The research was conducted by sampling accord-
ing to the location of the drugstore and in accordance with the area of capacity in the 
workers of ANVISA. RESULTS: there were interviewed 105 consumers in drugstores 
and 140 workers of ANVISA. When asked about the existence of market regulation 
of drugs, 51.43% and 87.14% of drug users and employees of ANVISA, respectively, 
said there is regulation of these products. About the PMC, the knowledge was 20.00% 
of respondents in pharmacies and 57.86% of the employees of ANVISA. Despite of 
the relative knowledge of PMC, only 01 of the respondents knew where consumers 
search the PMC, and the employees of ANVISA, 29 knew the sources of research. 
Although the poor knowledge on the regulation of prices, 84.76% of consumers 
interviewed considered this activity exerted by the government as important. CON-
CLUSIONS: Although the population consider important that the prices of medicines 
are regulated by the government, the knowledge of the regulation is small, even on 
the tools of consumer protection.
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INDEPENDENT RETAIL PHARMACY ATTRIBUTES, INSURER 
REIMBURSEMENT, AND THE IMPLICATION ON THE PROPOSED 
COLLECTIVE BARGAINING LAW
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OBJECTIVES: 1) To examine whether small individual provider attributes affects 
reimbursement between insurer and independent retail pharmacies, and 2) to under-
stand the implication of our results on the potential impact of the proposed community 
pharmacy collective bargaining law. METHODS: Data were collected and compiled 
from four sources: a national mail survey to independent pharmacies, National 
Council for Prescription Drug Programs Pharmacy database, 2000 U.S. Census and 
2006 Economic Census data. Pharmacy bargaining power was calculated using the 
costs, cash prices and reimbursement rates of a brand name drug Lipitol and a generic 
drug Lisinopril acquired from the survey. Key independent variables include individual 
pharmacy attributes and local market structure measures. RESULTS: Reimbursements 
varied substantially across pharmacies. For Lipitor, best reputation (β = 0.101), easiest 
accessibility (β = 0.067), pharmacy ownership concentration index (β = 0.104) and 
area per capita income (β = −0.165) are signiﬁcant predictors of pharmacy bargaining 
power. For Lisinopril, only easiest access (β = 0.082) and per capita income (β = 
−0.068) are found to be signiﬁcant. CONCLUSIONS: Pharmacies with the best repu-
tation, easiest access and facing less competition in its market receive higher reimburse-
ment rates for brand name drugs. An independent pharmacy with the best reputation 
and easiest access and with average dispensing volume would receive $167,688 more 
in reimbursement a year than a pharmacy that doesn’t have the best reputation and 
easiest access. Our results suggest that the current third party contracting practice 
rewards pharmacies with favorable attributes with higher reimbursements. Our results 
also imply that a collective bargaining law for independent pharmacies is likely to 
beneﬁt those pharmacies currently receiving below average reimbursement rates due 
to weaker market positions, and would have the potential effect of raising costs and 
removing incentives for pharmacies to maintain the attributes that are valuable to 
customers.
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OBJECTIVES: To evaluate treatment group differences in clinician reported ease of 
use between Fibrin Pad (FP) and Surgicel for hemostasis in subjects with mild or 
moderate bleeding using a novel survey tool. METHODS: The Ease of Use Question-
naire (EUQ) was used as part of a randomized, controlled, clinical study of FP versus 
Surgicel for intra-operative hemostasis. Subjects were randomized at 11 institutions 
with a 2:1 FP to Surgicel ratio. Additional subjects were enrolled in the non-random-
ized phase and treated with FP. Subjects were stratiﬁed according to bleeding severity. 
Up to the ﬁrst three subjects completed the EUQ at each institution. The ﬁnal sample 
was N = 20 FP and N = 8 Surgicel (randomized) and N = 2 FP (non-randomized). 
The EUQ is a 19-item instrument evaluating clinicians’ perceptions and preferences 
for hemostasis products on ﬁve subscales (Ease of Use, Satisfaction with Product 
Properties and Efﬁciency, Conﬁdence in Efﬁcacy, Global Conﬁdence, and Global 
Satisfaction).1 Differences in ease of use between treatment groups were evaluated 
using ﬁve ANCOVA models where subscale scores were the dependent variables, 
treatment group was the independent variable, and severity of bleeding was controlled 
for as the covariate. RESULTS: Mean subscale scores for Conﬁdence in Efﬁcacy (FP 
= 4.70 vs. S = 3.50), Global Conﬁdence (FP = 4.70 vs. S = 4.13) and Global Satisfac-
tion (FP = 4.85 vs. S = 4.04) were signiﬁcantly higher for the FP group as compared 
to the Surgicel group (all p < 0.05). Mean subscales scores for Ease of Use (FP = 4.82 
vs. S = 4.66) and Satisfaction (FP = 4.71 vs. S = 4.34) were higher for the FP group, 
but non-signiﬁcant. CONCLUSIONS: Physicians reported higher ease of use, satisfac-
tion, and global conﬁdence with FP for hemostasis in mild to moderate bleeding. 
Non-signiﬁcant results in the Ease of Use and Satisfaction subscales likely resulted 
from small sample sizes. Future studies should evaluate ease of use in the full range 
of bleeding severities and larger sample sizes.
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OBJECTIVES: Limited information is currently available regarding outcomes related 
to orthotics and prosthetics (O&P). Rapidly emerging technologies in the O&P ﬁeld 
have increased the need for comparative effectiveness studies examining clinical, 
humanistic, and economic outcomes. The objective of this project was to establish and 
pilot test a patient registry for outcomes assessment. METHODS: A web-based survey 
system combining input from both O&P providers and their patients was developed 
and pilot-tested among nine O&P clinics across the country. The providers entered 
